An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital

Etude Des Facteurs Explicatifs Des Coûts de la Prise En Charge Des Patients Adultes Atteints d'Une MICI Suivis au CHRU de Nancy et traités Par biothérapie

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03248024

Acronym

FECPEC MICI

Enrollment

119

Registered

2017-08-14

Start date

2016-11-28

Completion date

2017-02-07

Last updated

2017-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

Chronic Disease, Ulcerative Colitis

Brief summary

The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or adalimumab), including biosimilars (infliximab biosimilars: Inflectra ™ and Remsima ™) for treating Crohn's desease or ulcerative colitis

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients consulted at the Gastroenterology services of Nancy University Hospital during the period of inclusion 2. Patients over 18 of age the day of consultation 3. Patients treated at least one time by biotherapy during the last 12 months preceeding inclusion 4. Patients with crohn's disease or ulcerative colitis. 5. Patients accepting to respond to the questionnary

Exclusion criteria

* Age under 18 years , the day of consultation * Patient that not accept or unable to complete the retrospective questionnary

Design outcomes

Primary

Measure	Time frame	Description
Retrospective health care consumption	one year	Desease treatment cost individual level data

Outcome results